ProCE Banner Activity

CE / CME

CAR T-Cell Therapy Comes of Age in Hematologic Malignancies

Interactive Video Lecture

The efficacy of chimeric antigen receptor (CAR) T-cell therapy in previously incurable hematologic malignancies represents a promising paradigm shift in cancer care. With the approval of several different CAR T-cell products across several cancer types, expert guidance is urgently needed on the latest safety and efficacy data with these novel therapies. The unique acute toxicities of CAR T-cell therapies can require intensive monitoring and prompt management; education regarding the range, intensity, and management of adverse events of CAR T-cell therapy is essential to optimize patient care. This activity provides expert advice on the use of CAR T-cell therapy across hematologic malignancies, with discussions of supporting data and adverse event recognition and management.

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit
Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: January 31, 2022

Expiration: January 30, 2023

Begin Activity

Share

Faculty

Matthew Frigault

Matthew Frigault, MD

Instructor of Medicine
Harvard Medical School
Clinical Director
Cellular Immunotherapy Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Beth Sandy

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Acknowledgement

This program was cosupported by educational grants from Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

This activity is supported by educational grants from Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify the appropriate use of CAR T-cell therapy in hematologic malignancies

  • Summarize evidence for the efficacy and safety of CAR T-cell therapy in hematologic malignancies

  • Describe the recommended management of the most common toxicities associated with CAR T-cell therapy

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr Frigault: consulting fees: Arcellx, Bristol-Myers Squibb, Iovance; consulting fees/contracted research: Kite, Novartis.

Ms Sandy: fees for non-CME/CE services: Amgen, AstraZeneca, Jazz, Merck, Takeda.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Ms Sandy as noted above.

CME Info

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: January 31, 2022
Expiration date: January 30, 2023

Format

Interactive video lecture

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 30, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.